Viridian Therapeutics Ownership | Who Owns Viridian Therapeutics?
Viridian Therapeutics Ownership Summary
Viridian Therapeutics is owned by 132.50% institutional investors, 0.14% insiders. Fmr is the largest institutional shareholder, holding 18.14% of VRDN shares. Vanguard Total Stock Mkt Idx Inv is the top mutual fund, with 3.03% of its assets in Viridian Therapeutics shares.
VRDN Ownership Benchmark
| Type | Name | % Inst | % Insiders | % Retail |
|---|---|---|---|---|
| Stock | Viridian Therapeutics | 132.50% | 0.14% | -32.64% |
| Sector | Healthcare Stocks | 35.58% | 11.87% | 52.55% |
| Industry | Biotech Stocks | 35.75% | 11.83% | 52.41% |
Institutional Shareholders
Top Institutional Shareholders by Total Shares
| Holder | Shares | % Holding | Value |
|---|---|---|---|
| Fmr | 15.38M | 18.14% | $300.82M |
| Blackrock funding, inc. /de | 7.83M | 9.23% | $153.18M |
| Bellevue group | 6.73M | 7.93% | $131.56M |
| Blackrock | 4.77M | 7.81% | $62.10M |
| Vanguard group | 5.61M | 6.86% | $174.65M |
| State street | 4.67M | 5.51% | $91.40M |
| Fairmount funds management | 3.91M | 4.62% | $76.57M |
| Vr adviser | 3.88M | 4.58% | $75.95M |
| Commodore capital lp | 3.20M | 3.92% | $69.06M |
| Price t rowe associates inc /md/ | 3.21M | 3.78% | $62.71M |
Top Institutional Shareholders by % of Total Assets
| Holder | Shares | % Assets | Value |
|---|---|---|---|
| Fairmount funds management | 3.91M | 5.53% | $76.57M |
| Commodore capital lp | 3.20M | 3.37% | $69.06M |
| Novo | 2.00M | 3.17% | $39.12M |
| Bellevue group | 6.73M | 3.13% | $131.56M |
| Vr adviser | 3.88M | 2.83% | $75.95M |
| Kynam capital management, lp | 2.34M | 2.83% | $45.80M |
| Propel bio management | 210.16K | 2.58% | $4.09M |
| Ghost tree capital | 587.71K | 2.39% | $7.65M |
| Knott david m jr | 181.00K | 2.11% | $3.54M |
| First turn management | 911.34K | 1.99% | $17.83M |
Top Buyers
| Holder | Shares | % Assets | Change |
|---|---|---|---|
| Bellevue group | 6.73M | 3.13% | 2.37M |
| Balyasny asset management | 2.32M | 0.06% | 1.81M |
| Paradigm biocapital advisors lp | 3.15M | 1.26% | 1.71M |
| Citadel advisors | 2.32M | 0.01% | 1.64M |
| Blackrock funding, inc. /de | 7.83M | 0.00% | 1.40M |
Top Sellers
| Holder | Shares | % Assets | Change |
|---|---|---|---|
| Maverick capital | - | - | -2.21M |
| Ecor1 capital | - | - | -1.96M |
| Perceptive advisors | 1.17M | 0.45% | -1.87M |
| Commodore capital lp | 3.20M | 3.37% | -1.68M |
| Deep track capital, lp | 1.39M | 0.45% | -1.13M |
New Positions
| Holder | Shares | % Assets | Change | Value |
|---|---|---|---|---|
| Bioimpact capital | 649.87K | 0.98% | 649.87K | $12.71M |
| Vanguard fiduciary trust | 591.23K | 0.00% | 591.23K | $11.56M |
| Renaissance | 203.10K | 0.01% | 203.10K | $3.97M |
| Frontier capital management | 158.37K | 0.03% | 158.37K | $3.10M |
| Norges bank | 122.79K | 0.00% | 122.79K | $3.82M |
Sold Out
| Holder | Change |
|---|---|
| True wealth design | -4.00 |
| Nelson, van denburg & campbell wealth management group | -8.00 |
| Principal securities | -9.00 |
| Creative financial designs inc /adv | -10.00 |
| Montag a & associates | -12.00 |
Institutional Ownership Trends
| Date | Holdings | Change % | Shares | Change % | Ownership | Change % | Increased Position | Change % | Decreased Position | Change % |
|---|---|---|---|---|---|---|---|---|---|---|
| Mar 31, 2026 | 229 | -1.72% | 112,362,814 | 4.21% | 132 | 0.76% | 130 | -18.75% | 65 | 41.30% |
| Dec 31, 2025 | 145 | -17.14% | 44,766,785 | -51.97% | 54 | 0.42% | 101 | 46.38% | 28 | -57.58% |
| Sep 30, 2025 | 172 | -1.15% | 92,157,310 | -2.54% | 112 | 0.84% | 68 | -21.84% | 65 | 1.56% |
| Jun 30, 2025 | 174 | -1.69% | 94,556,349 | 8.58% | 115 | 1.01% | 87 | -6.45% | 64 | 16.36% |
| Mar 31, 2025 | 179 | -6.28% | 91,344,327 | 0.33% | 112 | 0.60% | 92 | -24.59% | 55 | 34.15% |
Top Mutual Funds Shareholders
| Holder | Shares | % Holding | Change |
|---|---|---|---|
| Vanguard Total Stock Mkt Idx Inv | 3.13M | 3.03% | 6.18K |
| Fidelity Select Health Care | 2.96M | 2.87% | 140.50K |
| State Street® SPDR® S&P® Biotech ETF | 2.94M | 2.85% | -29.40K |
| Vanguard US Total Market Shares ETF | 2.24M | 2.75% | 324.50K |
| iShares Russell 2000 ETF | 1.91M | 1.87% | 16.12K |
| Fidelity Advisor Biotechnology I | 1.78M | 1.73% | - |
| Fidelity Advisor Health Care I | 1.50M | 1.46% | - |
| Fidelity Small Cap Growth | 1.27M | 1.23% | - |
| Strategic Advisers Fidelity US TtlStk | 1.19M | 1.16% | 277.80K |
| SPDR® S&P Biotech ETF | 931.02K | 1.14% | 2.08K |
Recent Insider Transactions
| Date | Name | Role | Activity | Value |
|---|---|---|---|---|
| May 11, 2026 | Fairmount Funds Management LLC | Buy | $20.00M | |
| Dec 31, 2025 | Tousignant Jennifer | Chief Legal Officer | Sell | $70.80K |
| Oct 23, 2025 | Fairmount Funds Management LLC | Buy | $10.00M | |
| Sep 27, 2024 | Beetham Thomas W. | Chief Operating Officer | Buy | $117.05K |
| Sep 27, 2024 | Mahoney Stephen F. | President and CEO | Buy | $499.26K |
Insider Transactions Trends
| Date | Buy | Sell |
|---|---|---|
| 2026 Q2 | 1 | - |
| 2026 Q1 | - | - |
| 2025 Q4 | 1 | 1 |
| 2025 Q3 | - | - |
| 2025 Q2 | - | - |
VRDN Ownership FAQ
Try Tickergate Pro Free
Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)
Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis
Discover trending investment themes
Find your next best investment
Research stocks using tools